HER2/EGFR in Cancer Research
Peer reviewed
Scollr summary
What this paper is about
T-DM1 demonstrated heterogenous efficacy among HER2-amplified tumor types, with promising response and outcomes among patients with salivary gland cancer.
Full abstract
Read the full abstract
PURPOSE: To evaluate the efficacy of ado-trastuzumab emtansine (T-DM1) among patients with advanced/metastatic HER2-amplified solid tumors. PATIENTS AND METHODS: This was a single-center, non-randomized phase 2 basket trial conducted at Memorial Sloan Kettering Cancer Center. All 95 patients had HER2-amplified metastatic/advanced disease and were enrolled in 1 of 5 cohorts. HER2 amplification was diagnosed either with next-generation sequencing or in-situ hybridization. All patients received intravenous T-DM1 3.6 mg/kg every 21 days. The primary endpoint was overall response rate (ORR). Overall survival (OS), progression-free survival (PFS), duration of response (DOR), and safety were secondary endpoints. RESULTS: We treated 95 patients, and 22 (23% [95% CI, 16-33%]) had a confirmed response by investigator assessment. The investigator-assessed confirmed ORRs by cohort were: salivary 11/19 (58% [95% CI, 36-77%]); lung 4/23 (17% [95% CI, 7-37%]); colorectal 0/7 (0% [95% CI, 0-35%]); endometrial 5/23 (22% [95% CI, 10-42%]); "other" 2/23 (9% [95% CI, 2-27%]). Median PFS was 3.6 months (95% CI, 2.6-5.4) and ranged from 1.4 months in the "other" cohort to 10.2 months in the salivary cohort. Median OS was 11.9 months (95% CI, 8.4-17.2) and ranged from 7.8 months in the "other" cohort to 29.2 months in the salivary cohort. Median DOR was 13.1 months (95% CI, 7.3-30.5), ranging from 6.4 months in the lung cohort to 18.4 months in the "other" cohort. CONCLUSIONS: T-DM1 demonstrated heterogenous efficacy among HER2-amplified tumor types, with promising response and outcomes among patients with salivary gland cancer.
Direct answer
What can I do from this paper page?
Use this page to scan "A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow HER2/EGFR in Cancer Research, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{Stuart2026Phase,
title = {A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial},
author = {Jessica C. Stuart and Winston Wong and Lauren Schoech and Alex Makhnin and Dazhi Liu and Ranieri Yllanes and Jonathan Loi and Ala'A Damrah and Amanda Johnson and Michelle S. Ginsberg and Vetri Sudar Jayaprakasam and Mark Dunphy and Ronglai Shen and Nora Katabi and Kanika Arora and Michael F. Berger and David B. Solit and Mark Jeng and Charles Hsu and Alexander Drilon and Vicky Makker and Gopa Iyer and Rona Yaeger and Gregory J. Riely and Mark G. Kris and Bob T. Li and Alan L. Ho and Jamie E. Chaft},
journal = {Clinical Cancer Research},
year = {2026},
doi = {10.1158/1078-0432.ccr-26-1566},
url = {https://doi.org/10.1158/1078-0432.ccr-26-1566}
}FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new HER2/EGFR in Cancer Research papers?
Follow HER2/EGFR in Cancer Research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app